ERBB2 and breast carcinoma: It is a heterogeneous disease and divided into four major molecular subtypes based on gene expression [2], of which the human epidermal growth factor receptor 2- (HER2-) positive subtype accounts for 15%–20% of breast cancers (BC) and is associated with a worse prognosis [3–5].